CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Elthera AG is developing an anti-L1CAM antibody as a novel immunotherapy for pancreatic and ovarian cancer. This treatment aims to inhibit tumor growth and improve survival rates for patients suffering from these aggressive cancers.
Over 170’000 people in Europe and more than 570’000 people worldwide are affected by pancreatic and ovarian cancer.
For pancreatic cancer there currently no efficient therapies available and most patients succumb to the disease within 1 year from diagnosis.
In ovarian cancer, first line chemotherapy usually leads to good response rates, however tumors recur in 80-90% of patients and in most cases become resistant to conventional chemotherapy, leading to a low overall 5 year survival rate of only…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
